Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: A 4-T proton MRS study
Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: A 4-T proton MRS study
复制标题
DOI：
10.1176/appi.ajp.162.2.394
复制
发表时间：
2005-02-01
影响因子：
17.7
通讯作者：
Brooks, WM
中科院分区：
文献类型：
--
作者：
Rowland, LM;Bustillo, JR;Brooks, WM
目的：作者的目标是在人体中测试 N-甲基-D-天冬氨酸受体 (NMDAR) 拮抗作用导致皮质谷氨酸活性增加的假设，正如精神分裂症 NMDAR 功能减退模型所提出的那样。方法：使用 4-T H-1 质子磁共振波谱 (H-1-MRS) 获取 10 名健康受试者接受亚麻醉剂量的双侧前扣带回的体内光谱。安慰剂或氯胺酮（一种 NMDAR 拮抗剂）。服用氯胺酮或安慰剂之前和之后进行的评估包括简要精神病评定量表、阴性症状评估量表、临床医生施行的解离状态量表和斯特鲁普任务。 结果：正如预测的那样，服用氯胺酮后，前扣带谷氨酰胺（谷氨酸神经递质释放的假定标志物）显着增加。这种增加与精神分裂症样阳性或阴性症状无关，但与 Stroop 表现有一定关系。结论：在人类和动物中，急性 NMDAR 功能低下状态与前扣带回谷氨酸能活性增加有关。
Objective: The authors' goal was to test in humans the hypothesis that N-methyl-D-aspartate receptor ( NMDAR) antagonism results in increased cortical glutamate activity, as proposed by the NMDAR hypofunction model of schizophrenia.Method: 4-T H-1 proton magnetic resonance spectroscopy (H-1-MRS) was used to acquire in vivo spectra from the bilateral anterior cingulate of 10 healthy subjects while they received a subanesthetic dose of either placebo or ketamine, an NMDAR antagonist. Assessments given before and after ketamine or placebo administration included the Brief Rating Psychiatric Rating Scale, the Scale for the Assessment of Negative Symptoms, the Clinician-Administered Dissociative States Scale, and the Stroop task.Results: As predicted, there was a significant increase in anterior cingulate glutamine, a putative marker of glutamate neurotransmitter release, with ketamine administration. This increase was not related to schizophrenia-like positive or negative symptoms but was marginally related to Stroop performance.Conclusions: In humans as in animals, an acute hypofunctional NMDAR state is associated with increased glutamatergic activity in the anterior cingulate.